Primary hepatocellular carcinoma associated with Wilson’s disease in a young woman

R. Guan¹, C.J. Oon¹, P.K. Wong¹, W.C. Foong² and A. Wee³

Departments of ¹Medicine, ²Surgery and ³Pathology, National University of Singapore, Singapore General Hospital, Singapore 0316.

Summary: A 27 year old woman with hepatolenticular degeneration (Wilson’s disease) was found to have primary hepatocellular carcinoma (PHC) three and a half years after she was started on treatment with D-penicillamine. The tumour was resected since when she has remained well. Her liver function tests were normal throughout the course of her disease. The available literature is reviewed and possible mechanisms for this association proposed.

Introduction

Primary hepatocellular carcinoma (PHC) is rarely associated with Wilson’s disease (Lygren, 1959; Girard et al., 1968; Kamakura et al., 1975; Terao et al., 1982; Wilkinson et al., 1983), although it is a common complication of long-standing cirrhosis especially associated with haemochromatosis and hepatitis B infection. In women of child bearing age PHC is rare; most tumours appear in older women (Oon et al., 1979) and even then, they are far outnumbered by men with this malignancy. We report the occurrence of PHC in a young woman with Wilson’s disease who had never been on oral contraceptives or exposed to hepatitis B virus.

Case report

A female Chinese, first presented in 1976 at the age of 21 with difficulty in writing and frequent falls from an unsteady gait. Later she developed muscular weakness and dysphagia to both solids and liquids. Examination then revealed diminished motor power with persistent effort and myasthenia gravis was suspected. Repeated tension tests however were negative. Her dysphagia improved somewhat with amitriptyline. She was seen two years later with choreo-athetosis and dystonia. Kayser-Fleischer rings and hepatosplenomegaly were then noted and Wilson’s disease was confirmed by low serum caeruloplasmin oxidase activity to phenylenediamine hydrochloride and copper level of 6.4 mmol/l (40 μg/dl) (normal 12–26 μmol/l or 75–160 μg/dl), and a raised 24 h urinary copper excretion of 1.92 μmol (120 μg) increasing to 9.6 μmol, (600 μg) after D-penicillamine (normal 0.1–0.4 μmol or 5–25 μg per 24 h). Her liver function tests were normal. Family history and screening revealed no other siblings affected with Wilson’s disease or liver problems. She was started on D-penicillamine and made a slow recovery of her central nervous system signs although dystonia was still present after 3 years of therapy (750–1000 mg D-penicillamine daily). Her liver function tests remained normal during this period.

In 1981, at the age of 27, she presented with a six week history of epigastric pain which was referred to the left shoulder. She did not drink and had never been on any hormonal contraceptive. A hard, nodular left lobe of the liver was felt with its edge 12 cm from the xiphisternum. The spleen was just palpable.

Investigations showed normal serum transaminases, bilirubin and alkaline phosphatase. Hepatitis B surface antigen (HBsAg) (EIA), anti-HBs antibody (RIA), and anti-HBc antibodies (RIA) were all absent. α-feto protein was positive at 27,000 ng/dl (RIA). Colloid indium liver scan showed an enlarged liver with no uptake in the left lobe. A selective hepatic angiography suggested deviation of the aorta to the right by a vascular tumour which has replaced the left lobe of the liver. This appeared resectable. There were calcified shadows just below the left hemidiaphragm which was thought to be due to tumour calcification (Figure 1).

At operation, a large PHC involving the left lobe of the liver was found. There was also macronodular cirrhosis. The common bile duct contained a solitary...
copper concentration measured by atomic absorption spectrophotometry was 104 μg/g dry weight (normal <55 μg/g dry weight). Her post-operative recovery was uneventful and she has had no recurrence of her hepatoma to date.

**Discussion**

Wilson’s disease is a rare, hereditary disorder of copper metabolism and homeostasis. Impaired lysosomal copper excretion into the bile leads to copper accumulation in the body (Sternlieb et al., 1973), starting in the liver which initially displays an astonishing capacity to bind this metal (up to fifty times or more the normal concentration). No overt disease is seen at this stage. The binding capacity of the liver eventually becomes exceeded and copper induced liver damage occurs as the metal is released into the circulation and gets deposited in other tissues like the brain, kidneys and eyes. At the time of diagnosis, liver cirrhosis is usually well established (Deiss & Cartwright, 1971).

Only 5 cases of PHC associated with Wilson’s disease have been reported and all of them were males from 16 to 41 years old. Lygren (1959) suggested that malignant hepatoma in Wilson’s disease was probably secondary to cirrhosis when he described a 16 year old boy who died of PHC. Girard’s patient (1968) was a 41 year old farmer who presented at 19 years of age with neurological signs. Wilson’s disease was diagnosed three years afterwards but he was not treated with penicillamine till 17 years later at the age of 36. Histology revealed a trabecular type of PHC with biliary secretion in some areas. Macronodular cirrhosis was also present. Kamakura and co-workers (1975) described a 32 year old man with Wilson’s disease who was started on D-penicillamine only 18 months before his death from a massive intraperitoneal haemorrhage. He presented with neurological signs 5 years before treatment was instituted. The fourth patient was a 40 year old Japanese (Terao et al., 1982) who presented with tremors and slurring of speech 6 years before he was diagnosed and started on penicillamine and BAL. He died 11 years later. A 31 year old man with signs and symptoms of portal hypertension and liver insufficiency was reported by Wilkinson and fellow workers recently (1983). He was started on D-penicillamine 4 years after initial presentation but died 9 years later from liver failure. Hepatocellular carcinoma was diagnosed at necropsy.

Edmonson & Staines (1954) suggested that the development of PHC is proportional to the length of morbidity in cases of cirrhosis. Patients with Wilson’s disease tend to survive longer since the advent of early diagnosis and treatment with penicillamine. These long term survivors with cirrhosis may now present with PHC.
It has been shown experimentally that copper has an inhibitory effect on the factors responsible for PHC development in rats (Howell, 1958; Kammoto et al., 1973), although the level at which it is protective in man is unknown. This could be another explanation for the rarity of hepatoma in patients with Wilson’s disease and other diseases with longstanding cirrhosis and accompanying marked copper retention, such as primary biliary cirrhosis (6 cases reported to date: Krasner et al., 1979; Mallet et al., 1981; Terris et al., 1982) and sclerosing cholangitis (none as yet reported). All the 5 reported patients with hepatoma and Wilson’s disease have been treated with D-penicillamine which removes copper by chelating the excess metal. Hence the possible mechanisms for the development of PHC in our patient are a combination of macronodular cirrhosis consequent upon metal irritation and damage, and the lowering of liver copper to a level below that which is protective in the prevention of tumour formation.

Three cases of PHC complicating Wilson’s disease have been reported in the last 3 years compared to the same number over the previous 30 years. This could suggest an increasing incidence of this complication and seems to correspond with the increased usage of penicillamine for the above condition. The possible protective role of copper in PHC formation may be relevant to the use of penicillamine for its immunosuppressive and anti-collagen binding properties (Sherlock, 1981) in other chronic liver conditions.

References

Primary hepatocellular carcinoma associated with Wilson’s disease in a young woman.
R. Guan, C. J. Oon, P. K. Wong, W. C. Foong and A. Wee

Postgrad Med J 1985 61: 357-359
doi: 10.1136/pgmj.61.714.357

Updated information and services can be found at:
http://pmj.bmj.com/content/61/714/357

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/